Micro
Emerging
Active
Progresso da FDA da MDCXW e expansão da perspectiva clínica
Nova narrativa com cobertura limitada — ainda em formação.
Pontuação
0,5
Velocidade
▲ 0,0
Artigos
1
Fontes
1
Linha do Tempo de Sentimento
Linha do Tempo de Eventos
Mai 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Hipóteses
Pending
Prazo: 18 de Julho de 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Prazo: 15 de Novembro de 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Prazo: 17 de Agosto de 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Cronologia
Última atualizaçãoMai 19, 2026